Sentence examples for viable marker from inspiring English sources

Then came another blow: Technical workstations turned into a viable marker, and companies like Sun began to pick away at the minicomputer business.

SNP genotyping eliminates the need to identify viable marker features via permutation testing, relying instead on SNPs identified by genome resequencing methods.

Thus, the price and effort spent per viable marker on a SNP genotyping array is significantly lower than the price and effort spent on a SFP array, making SNP genotyping a clear improvement over SFP genotyping for use with BSA and XAM.

These findings in the well-characterized mouse model of apoptosis-induced liver injury suggest that serum fortilin levels represent a viable marker of in vivo apoptosis.

The identification of new genetic mutations as viable markers for therapeutic development is driving researchers and clinicians to focus on specific pathways for targeted therapies.

This method of identifying markers can be expensive given the low percentage of features that qualify as viable markers.

Furthermore, we show that UCP measurements are viable markers of nutritional status from single void urine samples and that it is unnecessary to collect complete 12 hour samples (as done by Wolden-Hanson and colleagues, [38]).

Although both serum and urine have been examined for viable markers, urinary compounds are generally considered to show a better reflection of renal inflammation and irreversible kidney damage [ 7- 9].

Yoshimoto and coworkers [ 48] reported that histologic grade and clinical stage, including lymph node metastasis, are important prognostic markers in breast cancer patients, which supports the notion that the downregulation of APC7 can be a viable prognostic marker.

These data suggest that HITS monitoring is not a viable surrogate marker for increased thromboembolic risk in such patients with DCM.

The aim of this study was (1) to determine the longitudinal progression of FVCpp in patients with MDC1A, analyzing both ambulatory and non-ambulatory cohorts as well as those on or not on ventilation support (VS) and (2) to determine if FCVpp is a viable outcome marker for progression of disease.